Navigation Links
Karen Walton-Bowen Joins Abt Bio-Pharma Solutions, Inc., as Senior Director, Biometrics
Date:10/22/2008

ded her M.Sc. in Medical Statistics by the University of London and earned her B.S. degree with honors in Mathematics & Computing from South Bank University, London, England. She is a member of the Royal Statistical Society, American Statistical Association, Drug Information Association, and the Association of Clinical Research Professionals. Ms. Walton-Bowen's work has been published in leading journals including Statistics In Medicine, The Journal of Pediatrics, and Annals of Allergy, Asthma & Immunology. She was also a contributor to Biopharmaceutical Sequential Statistical Applications, an important textbook on interim analyses with contributions from industry leaders.

The ABS team has provided integrated strategic, research, and commercialization services to the pharmaceutical, biotechnology, medical device, and diagnostics industries for more than 20 years. The company specializes in demonstrating the value, safety, and efficacy of health technologies through prospective studies such as registries as well as through retrospective data analyses, models, and quantitative and qualitative research. ABS teams of senior, seasoned staff help sponsors develop their research agendas, successfully conduct their research programs, and communicate the results to internal and external audiences. Primary service offerings include biometrics, clinical trials, registries and other late-phase clinical studies, health economics and outcomes research, pricing and reimbursement, and strategic commercialization services. Previously known as Abt Associates Clinical Trials, the company was renamed Abt Bio-Pharma Solutions and established as a wholly owned subsidiary of Abt Associates in April 2008.


'/>"/>
SOURCE Abt Bio-Pharma Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Health Monitoring Systems Appoints Karen S. Dockrell As VP, Sales
2. Food and Beverage Giant Joins Kannapolis Research Center
3. Mark Sutherland Joins GenVault as Senior Vice President, Business Development
4. Chief Technology Officer Joins ACAMP
5. Charles C. Harwood, Jr., Joins Cellectar, Inc.s Board of Directors
6. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
7. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
8. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
9. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
10. GM Exec Joins Bio-Reaction Industries Board of Directors
11. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 ... Paris in December 2011, ... of yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular ... expected late 2016.   SARAH, a large ... cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, ...
(Date:3/3/2015)... March 3, 2015 NASA astronaut Scott Kelly ... month to spend a year living and working on the ... from 5:30 to 7 a.m. EDT Monday, March 9. ... as he completes the final weeks of his training. The ... on NASA Television highlighting his mission training and previous spaceflights. ...
(Date:3/3/2015)... March 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), ... technologies and products for advanced microarray diagnostics, today ... CFE  to its Management team. In his capacity ... its transition from a development stage to a ... advance the Company,s capital market strategy and to ...
(Date:3/3/2015)... 3, 2015 Fried, Frank, Harris, Shriver & ... has joined the Firm as a partner in ... New York office. Mr. Lewis concentrates ... well as other intellectual property and general litigation. A ... represents both plaintiffs and defendants in a range of ...
Breaking Biology Technology:Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3
... Position in Emerging RNAi Industry through,Addition of ... Structural IP, PALO ALTO, Calif., April ... of targeted, systemic RNA interference (RNAi),therapeutics, today ... (IP) covering certain efficacy-enhancing structural elements of,small ...
... payments on future ... ... Inc.,("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company dedicated to,the research ... announced today that its subsidiary GeneSense,Technologies, Inc. ("GeneSense") has signed an ...
... Colo., April 8, 2008 HemoGenix(R),Inc., a privately-held ... USPTO has issued the first two of several ... the 21st,century answer and the only alternative to, ... first described in 1966., HALO(R) was developed ...
Cached Biology Technology:Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 2Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 3Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 2Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 5HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO). 2HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO). 3
(Date:2/25/2015)... Feb. 25, 2015  ABC Financial Services (ABC), ... the Health and Fitness Industry, today announced enhancements ... MYiCLUBonline.  The latest upgrade includes advances to the ... cardless check-in via Identity One fingerprint biometrics. The ... through interactive displays at the International Health, Racquet ...
(Date:2/19/2015)... , Feb .19, 2015 Research and Markets ... addition of the "Military Electro-Optical / Infrared ... Technology, by Platform - Forecast to 2020" ... military electro-optical/infrared systems market is expected to reach ... of 7.71%. This report segments the ...
(Date:2/11/2015)... According to a ... Product (Cards and Readers, Biometrics, Controllers, Management Software), ... Healthcare, Education) and By Geography - Global Forecast and Analysis to ... Control Market is expected to reach $10.4 ... of 10.6% between 2014 and 2020. ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... In the largest genome-wide study of brain aneurysms ever conducted, ... of Medicine have identified three new genetic variants that increase ... massive study of intracranial aneurysms involved more than 20,000 subjects ... the journal Nature Genetics . The new study, the ...
... what they want, to paraphrase the Rolling Stones, but sometimes ... that will appear in the May issue of the ... broad sweep of evolutionary changes in life on earth as ... shifts. And yet the amount of variability seen among successive ...
... Ore. April 2, 2010. Countless studies and reports exist describing ... the impact on the soil? Should one leave the debris ... in preparation for replanting the area in the future? , ... that the debris remaining on the ground after logging may ...
Cached Biology News:New genetic risk factors for aneurysms identified by Yale-led team 2Ecologists receive mixed news from fossil record 2Study reveals that logging debris suppresses development of an invasive competitor, Scotch broom 2
...
... and pathophysiological stressful conditions trigger the synthesis ... heat shock proteins (HSPs), more appropriately called ... Hsp90 family of proteins in mammalian cells ... and Trap-1 (Hsp75). It was found that ...
Custom LNA Oligonucleotide synthesis ,High quality Custom LNA Oligonucleotides are available for a variety of different specialty applications and innovative products. ,Please inquire for further...
... We deliversoluble protein or No Charge ... the best soluble protein results , 24 ... submitted , Powerful results on your most ... Optimization Service (SOS) uses proprietary tools and ...
Biology Products: